Business UpdateMay 11, 2026, 07:01 AM
DBV Technologies Phase 3 VITESSE Trial Positive; BLA on Track
AI Summary
DBV Technologies announced positive topline results from its Phase 3 VITESSE trial for the VIASKIN® Peanut Patch in children aged 4-7 years, with a Biologics License Application (BLA) submission on track for the first half of 2026. The company also made significant progress in its COMFORT Toddlers and THRIVE studies for younger populations and successfully raised $386.2 million in capital, securing funding into Q2 2027. Additionally, DBV Technologies will hold its Annual Combined General Meeting on June 3, 2026, to approve 2025 financial statements, director renewals, compensation policies, and various capital authorizations.
Key Highlights
- Positive topline results from Phase 3 VITESSE trial for VIASKIN® Peanut Patch (4-7 years).
- Biologics License Application (BLA) for VIASKIN® Peanut Patch on track for US submission in H1 2026.
- Raised $386.2 million in capital between March 2025 and January 2026.
- Funding secured to support operations into Q2 2027, including potential US launch.
- Advanced COMFORT Toddlers (1-3 years) and initiated THRIVE (6-12 months) clinical trials.
- Annual Combined General Meeting scheduled for June 3, 2026.
- Shareholders to vote on 2025 financial statements and director renewals.
- Proposals include share buyback authorization and various capital increase delegations.